Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 293

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 293
---
       | 80.35 | % |
| Biconomy PTE.LTD(6)                                             |     |              |  12,500,000 |     |        |  5.44 | % |     |       |  5.32 | % |

| * | Less than 1% |

| (1) | Unless otherwise indicated, the business address of each of the following individuals is 960 San Antonio Road, Palo Alto, CA 94303. |

| (2) | Comprised of 6,835,937 shares issuable upon exercise of options exercisable within 60 days of October 6, 2025. Until the date on which all payments and all obligations under the Oramed Note have been paid in full in cash, the options will not be or become exercisable, eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions (including the proceeds of any corporate transaction) or have any voting rights in respect of, among other things, the Company or any of its respective current and future subsidiaries, successors and assigns. |

190

| (3) | Comprised of 6,835,937 shares issuable upon exercise of options exercisable within 60 days of October 6, 2025. Until the date on which all payments and all obligations under the Oramed Note have been paid in full in cash, the options will not be or become exercisable, eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions (including the proceeds of any corporate transaction) or have any voting rights in respect of, among other things, the Company or any of its respective current and future subsidiaries, successors and assigns. |

| (4) | Comprised of 781,250 shares issuable upon exercise of options exercisable within 60 days of October 6, 2025. Until the date on which all payments and all obligations under the Oramed Note have been paid in full in cash, the options will not be or become exercisable, eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions (including the proceeds of any corporate transaction) or have any voting rights in respect of, among other things, the Company or any of its respective current and future subsidiaries, successors and assigns. |

| (5) | Consists of 500,000 shares held directly, 181,804,849 shares held by Scilex, Inc